. Author manuscript; available in PMC: 2011 Apr 12.

Published in final edited form as: Clin Cancer Res. 2008 May 15;14(10):3077–3082. doi: 10.1158/1078-0432.CCR-07-4743

Table 4.

Multiple regression analysis of the age-adjusted effect of tipifarnib following two-cycle timed sequential therapy on duration of CR

Secondary AML	Adverse cytogenetics	HR (95% CI)	P
Yes	Yes	0.11 (0.03–0.46)	0.02
Yes	No	0.42 (0.12–1.40)	0.16
No	Yes	0.69 (0.21–2.24)	0.53
No	No	2.54 (0.75–8.56)	0.13

NOTE: Adjusted for age <65 versus >65 y (HR, 0.67; P = 0.09).

Abbreviation: 95% CI, 95% confidence interval.